[HTML][HTML] Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios
F Lucà, F Oliva, MG Abrignani, SA Di Fusco… - Journal of Clinical …, 2023 - mdpi.com
It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …
Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: A nationwide propensity score–weighted study
Background: Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs)
and warfarin have been extensively compared. However, population-based studies …
and warfarin have been extensively compared. However, population-based studies …
Correct dosing, adherence and persistence of DOACs in atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis
S Emanuel, RA Kaba, G Delanerolle, BCT Field… - Open …, 2023 - openheart.bmj.com
Background Chronic kidney disease (CKD) and atrial fibrillation (AF) are increasing in
prevalence globally and share common risk factors. Our aim was to characterise real-world …
prevalence globally and share common risk factors. Our aim was to characterise real-world …
Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial
Background The mobile atrial fibrillation application (mAFA-II) randomized trial reported that
a holistic management strategy supported by mobile health reduced atrial fibrillation-related …
a holistic management strategy supported by mobile health reduced atrial fibrillation-related …
Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study
MMA Toorop, Q Chen, VYIG Tichelaar… - European Heart …, 2021 - academic.oup.com
Aims Persistence with direct oral anticoagulants (DOACs) has become a concern in non-
valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied …
valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied …
Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIAAF
Background Clinical risk factors are common among patients with atrial fibrillation (AF), but
there are still limited data on their association with oral anticoagulant (OAC) treatment …
there are still limited data on their association with oral anticoagulant (OAC) treatment …
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
JJ Komen, ER Heerdink, OH Klungel… - European Heart …, 2021 - academic.oup.com
Aims Studies on adherence and persistence with non-vitamin K oral anticoagulant (NOAC)
treatment have relied on data from the early years of NOAC availability. We aimed to study …
treatment have relied on data from the early years of NOAC availability. We aimed to study …
Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: a cohort study
Objective To describe patterns of anticoagulation prescription and persistence for those
aged≥ 65 years with atrial fibrillation (AF). Methods Descriptive cohort study using …
aged≥ 65 years with atrial fibrillation (AF). Methods Descriptive cohort study using …
[HTML][HTML] Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study
A Mitchell, J Snowball, TJ Welsh, MC Watson… - BMC medicine, 2021 - Springer
Background Anticoagulation for stroke prevention in atrial fibrillation (AF) has, historically,
been under-used in older people. The aim of this study was to investigate prescribing of oral …
been under-used in older people. The aim of this study was to investigate prescribing of oral …
Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort
Objective To evaluate antithrombotic (AT) use in individuals with atrial fibrillation (AF) and at
high risk of stroke (CHA2DS2-VASc score≥ 2) and investigate whether pre-existing AT use …
high risk of stroke (CHA2DS2-VASc score≥ 2) and investigate whether pre-existing AT use …